Vivos Therapeutics, Inc.
VVOS
$0.53
-$0.04-6.66%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -122.37% | -90.10% | -36.08% | -18.91% | 28.17% |
| Total Depreciation and Amortization | 159.15% | 125.30% | 72.53% | 31.24% | 3.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 24.09% | -25.25% | -35.23% | 267.44% | 18.27% |
| Change in Net Operating Assets | 217.68% | 235.95% | 153.94% | -301.62% | -221.41% |
| Cash from Operations | -25.09% | -20.27% | -15.14% | -29.74% | -27.90% |
| Capital Expenditure | -315.03% | -312.15% | -71.65% | -135.85% | 24.62% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1,276.99% | -1,225.00% | -975.70% | -1,104.72% | 24.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -6.08% | -54.51% | -52.13% | -32.32% | 92.62% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -25.50% | 38.50% | -2.45% | -113.84% | -42.95% |
| Cash from Financing | 73.21% | 3.82% | -6.05% | 25.32% | 97.71% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.75% | -191.64% | -160.57% | -184.46% | 93.93% |